Rapid Medical completes $20 million Series C financing led by JAM Capital Partners and MicroPort Scientific Corporation

The round was led by JAM Capital Partners and MicroPort with participation from Agate JT, RocSon Medtech Fund and existing investors.

Rapid Medical is a privately-held medical device company based in Yokne’am Illit, Israel that develops innovative devices used for endovascular treatments. The company develops two proprietary, next-generation product families, including the TIGERTRIEVER, the first-ever controllable, fully visible stentriever designed to treat ischemic stroke patients, and the COMANECI, the first-ever controllable aneurysm neck-bridging device. For more information, please visit www.rapid-medical.com.

Lincoln acted as the exclusive placement agent to Rapid Medical, working closely with the company through all aspects of the financing round. The Lincoln team provided transactional and industry expertise, as well as closely managing all aspects of the process, including the preparatory, marketing, negotiation and due diligence phases of the transaction. The proceeds will be used for the completion of the TIGER U.S. IDE study and to support accelerating commercial growth of the company’s minimally invasive stroke treatment and prevention products worldwide.

Ronen Eckhouse, Rapid Medical’s CEO, said, “Lincoln was able to leverage their global team, which was instrumental in securing investments from a diverse group of investors that will allow us to continue to develop new technologies and grow our company.”

Rapid Medical completes $20 million Series C financing led by JAM Capital Partners and MicroPort Scientific Corporation
  • 2019
    Close Year
  • Healthcare
    Industry
  • Private
    Client Type
  • Financial | Cross-border
    Transaction Type
  • China | Israel | USA
    Countries
Lincoln understands the value of Rapid Medical’s technology and was a valued partner throughout the transaction.
Ronen Eckhouse
CEO of Rapid Medical

Meet our Senior Team